ESTEVE expands into US market with acquisition of Regis Technologies
Ella Day | August 1, 2025 | News story | Mergers and Acquisitions | Corporate, ESTEVE, Pharmacy, Regis Technologies, US pharma market, contract development and manufacturing organisation
ESTEVE (Esteve Química), based in Barcelona, Spain, has acquired Regis Technologies, a contract development and manufacturing organisation (CDMO) based in Chicago, US, in a strategic move to strengthen its footprint in the US pharma market.
The acquisition gives ESTEVE direct access to the US market, enabling the company to offer end-to-end services for small-molecule active pharmaceutical ingredients (API) – from pre-clinical development to commercial manufacturing. The agreement brings approximately 70 Regis staff into ESTEVE’s global team and expands its overall service capabilities.
Founded in 1956, Regis Technologies has over six decades of experience providing process research and development, analytical services, API manufacturing, and chemistry, manufacturing and controls support, alongside a broad chromatography product portfolio.
“We are proud to strengthen our CDMO solutions for pharma innovators through this acquisition,” said Joan Petit, chief industrial operations officer of ESTEVE. “This move expands our global manufacturing footprint and enhances our capacity to support early-stage drug development.”
Scott Aladeen, CEO of Regis, added: “We are happy to join a company that shares our values – family-owned, people-focused and committed to long-term customer value.”
The acquisition follows ESTEVE’s broader strategy to strengthen its position as a global CDMO specialist. With facilities in Spain, Mexico and China, and now a US presence, it is positioned to provide integrated development and manufacturing services for complex pharmaceutical projects globally.
Ella Day
1/8/25
Related Content
Ascend granted certification for quality control testing at Munich facility
Ascend Advanced Therapies, a contract development and manufacturing organisation based in Maryland, US, has received …
Neogap Therapeutics selected to join EIC Soft-landing Programme, supporting international growth
Swedish biotech company, Neogap Therapeutics, has been selected to participate in the EIC Soft-landing Programme …
